Document is current
Any future updates will be listed below
-
Authors
Mahgoub, Thamir M.
Jordan, Emmet J.
Mahdi, Amira F.
Oettl, Veronika
Huefner, Stefanie
O’Donovan, Norma
Crown, John
Collins, Denis M. https://orcid.org/0000-0003-1043-6169
-
Funding
Funding for this research was provided by:
The Caroline Foundation and the Cancer Clinical Research Trust (Charity No. CHY12210)
Cancer Clinical Research Trust
Science Foundation Ireland (20-SPP-3684)
Dublin City University
- License Information
-
More Information
Article History
Received: 28 July 2023
Accepted: 20 November 2023
First Online: 16 January 2024
Declarations
:
: T.M.M, E.J.J, V.O., S.H. and N.O.D. declare no conflicts of interest. A.F.M: Research funding (to institution): Puma Biotechnology. D.M.C: Research funding (to institution): Roche/Genentech, WntResearch, Puma Biotechnology, Inc.; Research materials: Sanofi. JC: Research funding (to institution): Eisai, Puma Biotechnology, Roche, Regeneron, Boehringer Ingelheim; Employment: OncoMark, Ltd.; Honoraria: Eisai, Puma Biotechnology; MSD Oncology, Pfizer, G1 Therapeutics; Novartis; Speaker’s Bureau: Boehringer Ingelheim, Genomic Health, Roche, Pfizer; Shares: OncoMark Ltd; Travel and accommodation expenses: Pfizer, MSD, Abbvie, Astrazeneca, Novartis.
